HRP20190817T1 - Ang2-vezujuće molekule - Google Patents
Ang2-vezujuće molekule Download PDFInfo
- Publication number
- HRP20190817T1 HRP20190817T1 HRP20190817TT HRP20190817T HRP20190817T1 HR P20190817 T1 HRP20190817 T1 HR P20190817T1 HR P20190817T T HRP20190817T T HR P20190817TT HR P20190817 T HRP20190817 T HR P20190817T HR P20190817 T1 HRP20190817 T1 HR P20190817T1
- Authority
- HR
- Croatia
- Prior art keywords
- ang2
- pharmaceutical composition
- binding molecule
- amino acid
- variable domain
- Prior art date
Links
- 102100034608 Angiopoietin-2 Human genes 0.000 title claims 10
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 title claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 108060003951 Immunoglobulin Proteins 0.000 claims 5
- 102000018358 immunoglobulin Human genes 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Claims (15)
1. Ang2-vezujuća molekula koja obuhvaća jednostruku varijabilnu domenu imunoglobulina, naznačena time, da navedena jednostruka varijabilna domena imunoglobulina obuhvaća tri regije određivanja komplementarnosti (CDR - engl. complementarity determining regions): CDR1, CDR2 i CDR3, pri čemu
CDR1 ima aminokiselinsku sekvencu prikazanu u SEQ ID NO: 168,
CDR2 ima aminokiselinsku sekvencu prikazanu u SEQ ID NO: 171, i
CDR3 ima aminokiselinsku sekvencu prikazanu u SEQ ID NO: 175.
2. Ang2-vezujuća molekula u skladu sa zahtjevom 1, naznačena time, da navedena jednostruka varijabilna domena imunoglobulina je VHH.
3. The Ang2-vezujuća molekula u skladu sa zahtjevom 2, naznačena time, da se navedena VHH sastoji od jednostruke varijabilne domene imunoglobulina koja ima sekvencu koja se sastoji od SEQ ID NO: 166.
4. The Ang2-vezujuća molekula prema bilo kojem od zahtjeva 1 do 3, naznačena time, da navedena VHH ili navedena jednostruka varijabilna domena imunoglobulina ima modifikaciju ili izmjenu na svojem N-završetku, gdje je navedena modifikacija zapravo odstranjivanje prve aminokiseline a navedena izmjena je zamjena prve aminokiseline s nekom drugom aminokiselinom.
5. Molekula nukleinske kiseline, naznačena time, da ona kodira Ang2-vezujuću molekulu prema bilo kojem od zahtjeva 1 do 4.
6. Vektor ekspresije, naznačen time, da on obuhvaća navedenu molekulu nukleinske kiseline u skladu sa zahtjevom 5.
7. Stanica domaćina, naznačena time, da ona prenosi jedan ili više vektora ekspresije u skladu sa zahtjevom 6.
8. Postupak proizvodnje Ang2-vezujuće molekule prema bilo kojem od zahtjeva 1 do 4, naznačen time, da obuhvaća sljedeće korake:
transfekciju stanice domaćina s jednim ili više vektora ekspresije u skladu sa zahtjevom 6,
kultiviranje navedene stanice domaćina, i
dobivanje i pročišćavanje navedene Ang2-vezujuće molekule.
9. Farmaceutski sastav, naznačen time, da kao djelatni sastojak, obuhvaća jednu ili više navedenih Ang2-vezujućih molekula u skladu s bilo kojim od zahtjeva 1 do 4, i najmanje jedan fiziološki prihvatljiv nosač.
10. Farmaceutski sastav prema zahtjevu 9, naznačen time, da nadalje obuhvaća jedno ili više dodatnih terapeutskih sredstava.
11. Farmaceutski sastav prema bilo kojem od zahtjeva 9 ili 10, naznačen time, da se upotrebljava u liječenju bolesti koja je povezana s učincima na angiogenezi posredovanima putem Ang2.
12. Farmaceutski sastav prema zahtjevu 11, naznačen time, da se upotrebljava u liječenju raka i kancerogenih bolesti.
13. Farmaceutski sastav prema zahtjevu 11, naznačen time, da se upotrebljava u liječenju bolesti oka.
14. Farmaceutski sastav za uporabu prema zahtjevu 13, naznačen time, da se kod navedene bolesti oka radi o staračkoj makularnoj degeneraciji ili dijabetičkoj retinopatiji.
15. Farmaceutski sastav prema zahtjevu 11, naznačen time, da se upotrebljava u liječenju kroničnih bolesti bubrega.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12162615 | 2012-03-30 | ||
| PCT/EP2013/056635 WO2013144266A1 (en) | 2012-03-30 | 2013-03-27 | Ang2-binding molecules |
| EP13718796.9A EP2831111B1 (en) | 2012-03-30 | 2013-03-27 | Ang2-binding molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190817T1 true HRP20190817T1 (hr) | 2019-06-28 |
Family
ID=48190468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190817TT HRP20190817T1 (hr) | 2012-03-30 | 2019-04-30 | Ang2-vezujuće molekule |
Country Status (27)
| Country | Link |
|---|---|
| US (5) | US20130259859A1 (hr) |
| EP (1) | EP2831111B1 (hr) |
| JP (1) | JP5970734B2 (hr) |
| KR (1) | KR102020255B1 (hr) |
| CN (1) | CN104321344B (hr) |
| AU (1) | AU2013241769B2 (hr) |
| BR (1) | BR112014023415B1 (hr) |
| CA (1) | CA2865464C (hr) |
| CL (1) | CL2014002393A1 (hr) |
| CY (1) | CY1122007T1 (hr) |
| DK (1) | DK2831111T3 (hr) |
| EA (1) | EA031182B1 (hr) |
| ES (1) | ES2729165T3 (hr) |
| HR (1) | HRP20190817T1 (hr) |
| HU (1) | HUE044263T2 (hr) |
| IL (1) | IL234234B (hr) |
| IN (1) | IN2014DN06904A (hr) |
| LT (1) | LT2831111T (hr) |
| MX (1) | MX350248B (hr) |
| NZ (1) | NZ628584A (hr) |
| PH (1) | PH12014502179A1 (hr) |
| PL (1) | PL2831111T3 (hr) |
| PT (1) | PT2831111T (hr) |
| RS (1) | RS58732B1 (hr) |
| SI (1) | SI2831111T1 (hr) |
| TR (1) | TR201908638T4 (hr) |
| WO (1) | WO2013144266A1 (hr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| WO2016057367A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
| JP2017532342A (ja) | 2014-10-17 | 2017-11-02 | アムジエン・インコーポレーテツド | 眼療法のためのアンジオポエチン−１及びアンジオポエチン−２を対象とする抗体 |
| CN107427577A (zh) * | 2015-03-31 | 2017-12-01 | 韦斯夸尔德有限公司 | 具有蛋白酶可切割接头的肽构建体 |
| PL3328886T3 (pl) * | 2015-07-29 | 2021-02-08 | Allergan, Inc. | Przeciwciała ang-2 o wyłącznie ciężkim łańcuchu |
| CA3040194A1 (en) * | 2016-10-13 | 2018-04-19 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature |
| KR102143132B1 (ko) * | 2016-12-26 | 2020-08-10 | 기초과학연구원 | 항 Ang2 항체를 포함하는 안구질환 예방 및 치료용 조성물 |
| EP3565839A4 (en) | 2017-01-05 | 2021-04-21 | Gensun Biopharma Inc. | CHECKPOINT REGULATOR ANTAGONISTS |
| US11198726B2 (en) * | 2017-06-02 | 2021-12-14 | Boerhinger Ingelheim International Gmbh | Anti-cancer combination therapy |
| CN108659130B (zh) * | 2018-05-28 | 2021-09-10 | 长春力太生物技术有限公司 | 一种抗癌胚抗原纳米抗体及其应用 |
| US11001635B2 (en) | 2018-06-29 | 2021-05-11 | Gensun Biopharma Inc. | Antitumor antagonists |
| JP7177284B2 (ja) * | 2019-02-25 | 2022-11-22 | ファームアブシン・インコーポレイテッド | 抗ａｎｇ２抗体及びその用途 |
| US20220185875A1 (en) * | 2019-03-18 | 2022-06-16 | Jiangsu Hengrui Medicine Co., Ltd. | Bispecific antibody specifically bound to vegf and ang2 |
| JP2022540571A (ja) | 2019-06-28 | 2022-09-16 | ゲンスン バイオファーマ、インコーポレーテッド | 変異したＴＧＦβ１－ＲＩＩ細胞外ドメインおよび免疫グロブリン足場で構成される抗腫瘍アンタゴニスト |
| CN111875706B (zh) * | 2020-07-16 | 2021-03-30 | 广州康盛生物科技股份有限公司 | 一种抗人IgE蛋白的单域抗体及其应用 |
| WO2022256820A1 (en) | 2021-06-03 | 2022-12-08 | Gensun Biopharma Inc. | Multispecific antagonists |
| WO2023035226A1 (zh) * | 2021-09-10 | 2023-03-16 | 深圳康哲医药发展有限公司 | 抗ang2抗体及其制备方法和应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2162823T5 (es) | 1992-08-21 | 2010-08-09 | Vrije Universiteit Brussel | Inmunoglobulinas desprovistas de cadenas ligeras. |
| US5643755A (en) | 1994-10-07 | 1997-07-01 | Regeneron Pharmaceuticals Inc. | Nucleic acid encoding tie-2 ligand |
| US5814464A (en) | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| IL156955A0 (en) | 2001-01-17 | 2004-02-08 | Genecraft Inc | Binding domain-immunoglobulin fusion proteins |
| JP4303105B2 (ja) | 2001-06-28 | 2009-07-29 | ドマンティス リミテッド | 二重特異性リガンドとその利用 |
| US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7205275B2 (en) | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
| EP2316852B1 (en) | 2002-11-08 | 2014-03-05 | Ablynx N.V. | Stabilized single domain antibodies |
| US20060228355A1 (en) | 2003-11-07 | 2006-10-12 | Toon Laeremans | Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor |
| EP1558646A2 (en) | 2002-11-08 | 2005-08-03 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses thereof |
| US20050284249A1 (en) | 2004-06-29 | 2005-12-29 | Arnone David F | Worm type gear mover assembly |
| AU2005293752A1 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as Alzheimer's disease |
| AU2005319382B2 (en) | 2004-12-21 | 2011-04-07 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
| PL1888640T3 (pl) | 2005-05-18 | 2012-08-31 | Ablynx Nv | Ulepszone nanociała skierowane przeciwko czynnikowi martwicy nowotworów typu alfa |
| RU2008152435A (ru) | 2006-06-06 | 2010-07-20 | Дженентек, Инк. (Us) | Композиции и способы регулирования развития сосудов |
| WO2008020079A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| US20110118185A9 (en) | 2007-02-21 | 2011-05-19 | Ablynx N.V. | Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization |
| CN101965362A (zh) | 2008-03-05 | 2011-02-02 | 埃博灵克斯股份有限公司 | 新型抗原结合二聚体-复合物及其制备方法和应用 |
| EP3424526A1 (en) * | 2008-06-05 | 2019-01-09 | Ablynx NV | Immunoglobulin single variable domains binding to the g envelope protein of rabies virus and uses thereof for the treatment and prevention of rabies |
| WO2010066836A2 (en) * | 2008-12-10 | 2010-06-17 | Ablynx Nv | Amino acid sequences directed against the angiopoietin/tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US20130078247A1 (en) * | 2011-04-01 | 2013-03-28 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to dii4 and ang2 |
| US9527925B2 (en) * | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
-
2013
- 2013-03-27 AU AU2013241769A patent/AU2013241769B2/en active Active
- 2013-03-27 MX MX2014011171A patent/MX350248B/es active IP Right Grant
- 2013-03-27 IN IN6904DEN2014 patent/IN2014DN06904A/en unknown
- 2013-03-27 CA CA2865464A patent/CA2865464C/en active Active
- 2013-03-27 BR BR112014023415-9A patent/BR112014023415B1/pt active IP Right Grant
- 2013-03-27 JP JP2015502346A patent/JP5970734B2/ja active Active
- 2013-03-27 DK DK13718796.9T patent/DK2831111T3/en active
- 2013-03-27 EA EA201401065A patent/EA031182B1/ru not_active IP Right Cessation
- 2013-03-27 WO PCT/EP2013/056635 patent/WO2013144266A1/en active Application Filing
- 2013-03-27 HU HUE13718796 patent/HUE044263T2/hu unknown
- 2013-03-27 PT PT13718796T patent/PT2831111T/pt unknown
- 2013-03-27 ES ES13718796T patent/ES2729165T3/es active Active
- 2013-03-27 PL PL13718796T patent/PL2831111T3/pl unknown
- 2013-03-27 CN CN201380026471.3A patent/CN104321344B/zh active Active
- 2013-03-27 SI SI201331449T patent/SI2831111T1/sl unknown
- 2013-03-27 EP EP13718796.9A patent/EP2831111B1/en active Active
- 2013-03-27 RS RS20190627A patent/RS58732B1/sr unknown
- 2013-03-27 NZ NZ628584A patent/NZ628584A/en unknown
- 2013-03-27 TR TR2019/08638T patent/TR201908638T4/tr unknown
- 2013-03-27 KR KR1020147028419A patent/KR102020255B1/ko active IP Right Grant
- 2013-03-27 LT LTEP13718796.9T patent/LT2831111T/lt unknown
- 2013-03-28 US US13/852,402 patent/US20130259859A1/en not_active Abandoned
-
2014
- 2014-08-21 IL IL234234A patent/IL234234B/en active IP Right Grant
- 2014-09-10 CL CL2014002393A patent/CL2014002393A1/es unknown
- 2014-09-29 PH PH12014502179A patent/PH12014502179A1/en unknown
-
2016
- 2016-12-21 US US15/386,181 patent/US20170107281A1/en not_active Abandoned
-
2018
- 2018-07-02 US US16/025,067 patent/US20190135907A1/en not_active Abandoned
-
2019
- 2019-04-30 HR HRP20190817TT patent/HRP20190817T1/hr unknown
- 2019-06-18 CY CY20191100625T patent/CY1122007T1/el unknown
-
2020
- 2020-03-13 US US16/817,700 patent/US20200207845A1/en not_active Abandoned
-
2023
- 2023-03-17 US US18/185,493 patent/US20230203146A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190817T1 (hr) | Ang2-vezujuće molekule | |
| CY1120429T1 (el) | Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων | |
| HRP20161689T1 (hr) | Bispecifične vezne molekule koje se vežu na vegf i ang2 | |
| PH12014502713B1 (en) | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases | |
| TN2020000015A1 (en) | Interleukin-21 muteins and methods of treatment | |
| ECSP10010226A (es) | Compuestos derivados de amina para tratar enfermedades y trastornos oftálmicos | |
| WO2010048332A3 (en) | Compounds for treating ophthalmic diseases and disorders | |
| AU2016277883A8 (en) | PD-1-CD28 fusion proteins and their use in medicine | |
| HRP20161740T1 (hr) | Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b | |
| MX2019009255A (es) | Proteínas quiméricas dirigidas y sus usos. | |
| BR112018004078A2 (pt) | composições farmacêuticas, usos de proteinas de fusão e métodos para tratar câncer e para inibir a metástase em um indivíduo | |
| SG10201804945WA (en) | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof | |
| WO2013120012A3 (en) | Cdim binding proteins and uses thereof | |
| AR090047A1 (es) | Dominio variable dual de inmunoglobulinas y sus usos | |
| EA201590663A1 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ | |
| UY35195A (es) | Composiciones y metodos para proteinas de accion prolongada | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| NZ625403A (en) | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration | |
| CN106943596A (zh) | 用于治疗肿瘤的抗-cd20组合 | |
| BR112016022318A2 (pt) | método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo | |
| WO2013059559A3 (en) | Compounds and methods for enhancing innate immune responses | |
| EA201100462A1 (ru) | Серосвязанные соединения для лечения офтальмологических заболеваний и расстройств | |
| JP2014511682A5 (hr) | ||
| EA201490653A1 (ru) | Производные эстра-1,3,5(10),16-тетраен-3-карбоксамида, способ их получения, содержащие их фармацевтические препараты, а также их применение для получения лекарственных средств | |
| EP3492096A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF EYE DISEASES WITH CAS9 PROTEINS AND GUIDE RNA |